C12Y 302/02005
Nad+ nucleosidase
Official title: NAD+ nucleosidase (3.2.2.5)
C12Y302/02005 (Nad+ nucleosidase) appears on 7 US grants and 12 published applications in this corpus.
Search patents in C12Y- Granted patents
- 7
- Published applications
- 12
- Assignees
- 11
- Inventors
- 34
- Latest grant
- 19 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 0 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 2 | 1 |
| 2011 | 1 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 1 | 2 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating cancer with anti-CD38 immunotherapy19 Aug 2025US 12,391,958 B2Lentigen Technology, Inc.
- Compositions and methods for treating cancer with anti-CD38 immunotherapy31 Aug 2021US 11,103,533 B2Lentigen Technology, Inc.
- Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i1 Dec 2015US 9,200,061 B2Morpho Sys AG
- CD38 modulated chemotaxis27 Dec 2011US 8,084,035 B2Trudeau Institute
- Mutant forms of meningococcal ADP-ribosylating toxin28 Dec 2010US 7,858,096 B2Novartis AC
- Compositions and methods for artificial protospacer adjacent motif (pam) generation8 Jan 2026US 2026/0009051 A1Vor Biopharma Inc.
- Cd38 compositions and methods for immunotherapy2 Oct 2025US 2025/0302874 A1Intellia Therapeutics, Inc.
- Treatment of multiple myeloma8 Dec 2022US 2022/0389112 A1National University of Ireland, Galway
- Compositions and Methods for Treating Cancer with Anti-CD38 Immunotherapy18 Nov 2021US 2021/0353675 A1Lentigen Technology, Inc.
- Methods and reagent for analysing nucleic acids from individual cells28 Oct 2021US 2021/0332411 A1Autolus Limited
Most cited
By later US patents
- Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i16US 9,200,061 B2Morpho Sys AG · 2015
- Compositions and methods for treating cancer with anti-CD38 immunotherapy3US 11,103,533 B2Lentigen Technology, Inc. · 2021
- Methods for identifying compounds that inhibit CD38 activity1US 6,955,884 B2Trudeau Institute · 2005